Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At

Nucl Med Biol. 2004 Apr;31(3):357-64. doi: 10.1016/j.nucmedbio.2003.08.011.

Abstract

To exploit the fact that IL-2 receptors are expressed by T-cells responding to foreign antigens but not by resting T-cells, humanized anti-Tac (HAT) armed with alpha-emitting radionuclides (212)Bi and (211)At was evaluated in a cynomolgus cardiac allograft model. Control graft survival was 8.2+/- 0.5 days compared with 14.0+/-1.3 days (p<0.01) survival for monkeys treated with (212)Bi labeled HAT and 26.7+/-2.4 days survival (p<0.001 versus controls) with (211)At labeled HAT. Thus, (211)At labeled HAT may have application in organ transplantation and in treatment of IL-2 receptor expressing T-cell leukemia.

Publication types

  • Evaluation Study

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology*
  • Antibodies, Monoclonal / therapeutic use*
  • Astatine / immunology
  • Astatine / therapeutic use*
  • Bismuth / immunology
  • Bismuth / therapeutic use*
  • Female
  • Graft Rejection / immunology*
  • Graft Rejection / prevention & control
  • Graft Rejection / radiotherapy*
  • Graft Survival / immunology
  • Macaca fascicularis
  • Mice
  • Mice, Nude
  • Protein Subunits
  • Radioimmunotherapy / methods*
  • Radioisotopes / therapeutic use
  • Radiopharmaceuticals / immunology
  • Radiopharmaceuticals / therapeutic use
  • Receptors, Interleukin-2 / immunology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Protein Subunits
  • Radioisotopes
  • Radiopharmaceuticals
  • Receptors, Interleukin-2
  • Bismuth
  • Astatine